A Phase 3 interventional study of OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 148 sites in 19 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-10.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one has the largest enrollment, is one of 7 that started in 2011, is one of 16 in phase 3, and was the 5th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,044 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2011, is one of 50 in phase 3, and was the 38th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.
Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with a current Axis I diagnosis of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-34712
Phase A: 1-2 mgs/day by mouth, max of 4 wks. Phase B: 1-4 mgs/day by mouth, up to 52 weeks
Percentage of Participants With Adverse Events (AEs)
A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption or reduction of IMP.
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in Positive and Negative Syndrome Scale Total Score
The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS total score was sum of rating scores for 7 positive, 7 negative, and 16 general psychopathology subscale items of PANSS panel.
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Positive Subscale Score
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Negative Subscale Score
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking.
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale Score
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in Personal and Social Performance Scale Total Score
The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
Time frame: From Baseline up to 52 Weeks
Mean Clinical Global Impression - Improvement Score
The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due to the drug treatment. All responses were compared to the participant's condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: From Baseline up to 52 Weeks
Response Rate
Response rate was defined as a reduction of ≥ 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit.
Time frame: From Baseline up to 52 Weeks
Discontinuation Rate for Lack of Efficacy
Discontinuation rate for the participants who discontinued due to lack of efficacy were examined.
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in Positive and Negative Syndrome Scale Excited Component Score
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Positive Symptoms Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score was the sum of the 8 components (delusions (P1), hallucinatory behavior (P3), grandiosity (P5), suspiciousness/persecution (P6), stereotyped thinking (N7), somatic concern (G1), unusual thought content (G9) and lack of judgment and insight (G12)) of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Negative Symptoms Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items (blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity and conversation flow (N6), motor retardation (G7) and active social avoidance (G16)) of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Disorganized Thought Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items (conceptual disorganization (P2), difficulty in abstract thinking (N5), mannerisms and posturing (G5), disorientation (G10), poor attention (G11), disturbance of volition (G13) and preoccupation (G15)) on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Hostility/ Excitement Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items (excitement (P4), hostility (P7), uncooperativeness (G8) and poor impulse control (G14)) on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in PANSS Marder Factor Scores - Anxiety/Depression Score
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items (anxiety (G2), guilt feelings (G3), tension (G4) and depression (G6)) on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Time frame: From Baseline up to 52 Weeks
This trial was conducted in a total of 1072 participants (1044 of whom entered the open-label treatment phase) at 202 trial sites in the following 18 countries: Japan, Korea, Malaysia, Philippines, Taiwan, Croatia, Latvia, Poland, Romania, Russia, Serbia, Turkey, Ukraine, Columbia, Mexico, Canada, Puerto Rico, and United States of America (USA).
| Milestone | Prior Brexpiprazole | Prior Placebo | De Novo |
|---|---|---|---|
| Started | 12 | 0 | 227 |
| Completed | 12 | 0 | 199 |
| Not completed | 0 | 0 | 28 |
| Withdrew: Lost to follow-up | 0 | 0 | 6 |
| Withdrew: Adverse event | 0 | 0 | 8 |
| Withdrew: Subject met withdrawal criteria | 0 | 0 | 7 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 5 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Milestone | Prior Brexpiprazole | Prior Placebo | De Novo |
|---|---|---|---|
| Started | 611 | 204 | 229 |
| Completed | 308 | 109 | 91 |
| Not completed | 303 | 95 | 138 |
| Withdrew: Lost to follow-up | 22 | 12 | 22 |
| Withdrew: Adverse event | 109 | 23 | 27 |
| Withdrew: Subject met withdrawal criteria | 38 | 5 | 38 |
| Withdrew: Physician decision | 9 | 1 | 3 |
| Withdrew: Withdrawal by subject | 102 | 45 | 30 |
| Withdrew: Protocol deviation | 1 | 2 | 4 |
| Withdrew: Lack of efficacy | 22 | 7 | 14 |
A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment; or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption or reduction of IMP.
| percentage of participants | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| With AEs | 60.2 | 56.4 | 65.2 | 60.5 |
| With TEAEs | 60.0 | 56.4 | 65.2 | 60.4 |
| With SAEs | 14.9 | 8.9 | 11.2 | 12.9 |
The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS total score was sum of rating scores for 7 positive, 7 negative, and 16 general psychopathology subscale items of PANSS panel.
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -6.90 ± 12.90 | -12.50 ± 14.90 | -6.60 ± 13.60 | -8.00 ± 13.60 |
| At Week 52 (Participant count= 226,93,91,410) | -11.0 ± 14.40 | -18.40 ± 16.90 | -8.80 ± 12.60 | -12.20 ± 15.00 |
| At Last Visit (Participant count=591,198,223,1012) | -3.80 ± 16.70 | -9.70 ± 18.70 | -3.50 ± 14.30 | -4.90 ± 16.80 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -2.10 ± 4.50 | -4.10 ± 5.40 | -1.70 ± 4.30 | -2.40 ± 4.70 |
| At Week 52 (Participant count=226,93,91,410) | -3.20 ± 4.60 | -5.80 ± 5.20 | -2.30 ± 4.10 | -3.60 ± 4.80 |
| At Last Visit (Participant count=591,198,223,1012) | -0.90 ± 5.90 | -2.80 ± 6.40 | -1.00 ± 4.90 | -1.30 ± 5.80 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking.
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -1.40 ± 3.70 | -2.40 ± 4.30 | -1.30 ± 3.80 | -1.60 ± 3.90 |
| At Week 52 (Participant count=226,93,91,410) | -2.70 ± 4.50 | -3.70 ± 5.40 | -2.00 ± 3.70 | -2.80 ± 4.60 |
| At Last Visit (Participant count=591,198,223,1012) | -1.00 ± 4.10 | -2.40 ± 5.00 | -0.60 ± 4.20 | -1.20 ± 4.30 |
The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At at Week 26 (Participant count=375,134,123,632) | -0.35 ± 0.79 | -0.60 ± 0.98 | -0.24 ± 0.88 | -0.38 ± 0.86 |
| At Week 52 (Participant count=226,93,91,410) | -0.55 ± 0.86 | -0.97 ± 0.98 | -0.48 ± 0.86 | -0.63 ± 0.91 |
| At Last Visit (Participant count=591,198,223,1012) | -0.14 ± 1.04 | -0.46 ± 1.12 | -0.17 ± 0.88 | -0.21 ± 1.03 |
The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=366,134,123,623) | 4.50 ± 9.70 | 6.50 ± 11.30 | 4.50 ± 9.00 | 4.90 ± 10.00 |
| At Week 52 (Participant count=223,93,91,407) | 7.00 ± 10.60 | 9.60 ± 11.90 | 7.60 ± 10.80 | 7.70 ± 11.00 |
| At Last Visit (Participant count=569,196,219,984) | 1.80 ± 12.40 | 5.10 ± 12.80 | 2.70 ± 11.00 | 2.70 ± 12.20 |
The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due to the drug treatment. All responses were compared to the participant's condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=381,134,123,638) | 3.00 ± 1.13 | 2.77 ± 0.99 | 3.00 ± 1.13 | 2.95 ± 1.10 |
| At Week 52 (Participant count=226,93,91,410) | 2.66 ± 1.13 | 2.26 ± 0.97 | 2.76 ± 1.09 | 2.59 ± 1.10 |
| At Last Visit (Participant count=598,198,223,1019) | 3.31 ± 1.43 | 2.96 ± 1.33 | 3.30 ± 1.27 | 3.24 ± 1.38 |
Response rate was defined as a reduction of ≥ 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit.
| percentage of participants | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| Response Rate | 34.2 | 42.6 | 27.2 | 34.3 |
Discontinuation rate for the participants who discontinued due to lack of efficacy were examined.
| percentage of participants | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| Discontinuation Rate for Lack of Efficacy | 3.6 | 3.5 | 6.3 | 4.2 |
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -0.60 ± 3.10 | -1.80 ± 3.70 | -0.70 ± 3.10 | -0.90 ± 3.30 |
| At Week 52 (Participant count=226,93,91,410) | -1.20 ± 3.20 | -2.60 ± 3.40 | -1.00 ± 2.90 | -1.50 ± 3.20 |
| At Last Visit (Participant count=591,198,223,1012) | 0.10 ± 4.10 | -0.90 ± 4.20 | -0.30 ± 3.50 | -0.20 ± 4.00 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score was the sum of the 8 components (delusions (P1), hallucinatory behavior (P3), grandiosity (P5), suspiciousness/persecution (P6), stereotyped thinking (N7), somatic concern (G1), unusual thought content (G9) and lack of judgment and insight (G12)) of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -2.60 ± 4.80 | -4.70 ± 5.50 | -2.00 ± 5.20 | -2.90 ± 5.10 |
| At Week 52 (Participant count=226,93,91,410) | -3.90 ± 5.20 | -6.60 ± 5.70 | -2.60 ± 4.80 | -4.20 ± 5.40 |
| At Last Visit (Participant count=591,198,223,1012) | -1.60 ± 5.90 | -3.50 ± 6.50 | -1.30 ± 5.00 | -1.90 ± 5.90 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items (blunted affect (N1), emotional withdrawal (N2), poor rapport (N3), passive/apathetic social withdrawal (N4), lack of spontaneity and conversation flow (N6), motor retardation (G7) and active social avoidance (G16)) of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -1.50 ± 3.60 | -2.20 ± 4.00 | -1.70 ± 4.10 | -1.70 ± 3.80 |
| At Week 52 (Participant count=226,93,91,410) | -2.60 ± 4.30 | -3.90 ± 5.00 | -2.20 ± 3.80 | -2.80 ± 4.40 |
| At Last Visit (Participant count=591,198,223,1012) | -1.00 ± 4.10 | -2.30 ± 5.10 | -0.70 ± 4.10 | -1.20 ± 4.40 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items (conceptual disorganization (P2), difficulty in abstract thinking (N5), mannerisms and posturing (G5), disorientation (G10), poor attention (G11), disturbance of volition (G13) and preoccupation (G15)) on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -1.70 ± 3.30 | -2.60 ± 3.50 | -1.70 ± 3.50 | -1.90 ± 3.40 |
| At Week 52 (Participant count=226,93,91,410) | -2.90 ± 3.70 | -3.70 ± 4.60 | -2.30 ± 3.70 | -2.90 ± 4.00 |
| At Last Visit (Participant count=591,198,223,1012) | -1.20 ± 4.20 | -2.20 ± 4.50 | -0.90 ± 4.00 | -1.40 ± 4.20 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items (excitement (P4), hostility (P7), uncooperativeness (G8) and poor impulse control (G14)) on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -0.40 ± 2.70 | -1.40 ± 3.10 | -0.60 ± 2.60 | -0.60 ± 2.80 |
| At Week 52 (Participant count=226,93,91,410) | -0.80 ± 2.70 | -1.90 ± 2.90 | -0.90 ± 2.30 | -1.10 ± 2.70 |
| At Last Visit (Participant count=591,198,223,1012) | 0.20 ± 3.40 | -0.70 ± 3.50 | -0.30 ± 3.00 | -0.10 ± 3.40 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items (anxiety (G2), guilt feelings (G3), tension (G4) and depression (G6)) on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
| Units on a scale | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| At Week 26 (Participant count=375,134,123,632) | -0.70 ± 2.60 | -1.50 ± 3.00 | -0.70 ± 3.40 | -0.90 ± 2.90 |
| At Week 52 (Participant count=226,93,91,410) | -0.90 ± 2.50 | -2.40 ± 2.90 | -0.80 ± 3.50 | -1.20 ± 2.90 |
| At Last Visit (Participant count=591,198,223,1012) | -0.20 ± 3.20 | -0.90 ± 3.40 | -0.40 ± 3.80 | -0.40 ± 3.40 |
Collected over The trial required that participants be actively monitored for AEs up to 30 (+2) days after the last dose of study drug, up to 52 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| De Novo (Phase A) | — | 4/226 (1.8%) | 0/226 (0%) |
| Prior Brexpiprazole (Phase B) | — | 90/605 (14.9%) | 166/605 (27.4%) |
| Prior Placebo (Phase B) | — | 18/202 (8.9%) | 53/202 (26.2%) |
| De Novo (Phase B) | — | 25/224 (11.2%) | 95/256 (37.1%) |
| Event | De Novo (Phase A) | Prior Brexpiprazole (Phase B) | Prior Placebo (Phase B) | De Novo (Phase B) |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 2/226 | 68/605 | 12/202 | 10/224 |
| Psychotic disorderPsychiatric disorders | 1/226 | 7/605 | 3/202 | 4/224 |
| AnxietyPsychiatric disorders | 0/226 | 0/605 | 0/202 | 2/224 |
| Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/226 | 0/605 | 1/202 | 0/224 |
| Schizophrenia, Paranoid typePsychiatric disorders | 0/226 | 1/605 | 1/202 | 0/224 |
| Completed suicidePsychiatric disorders | 0/226 | 0/605 | 1/202 | 0/224 |
| Emotional disorderPsychiatric disorders | 0/226 | 0/605 | 1/202 | 0/224 |
| Cardiac failure congestiveCardiac disorders | 0/226 | 0/605 | 0/202 | 1/224 |
| Coronary artery diseaseCardiac disorders | 0/226 | 0/605 | 0/202 | 1/224 |
| Abdominal herniaGastrointestinal disorders | 0/226 | 0/605 | 0/202 | 1/224 |
| Event | De Novo (Phase A) | Prior Brexpiprazole (Phase B) | Prior Placebo (Phase B) | De Novo (Phase B) |
|---|---|---|---|---|
| InsomniaPsychiatric disorders | 0/226 | 51/605 | 17/202 | 32/256 |
| HeadacheNervous system disorders | 0/226 | 42/605 | 14/202 | 24/256 |
| Weight increasedInvestigations | 0/226 | 47/605 | 15/202 | 23/256 |
| AgitationPsychiatric disorders | 0/226 | 30/605 | 7/202 | 23/256 |
| HypertensionVascular disorders | 0/226 | 10/605 | 2/202 | 20/256 |
| AkathisiaNervous system disorders | 0/226 | 22/605 | 14/202 | 14/256 |
| Age, Continuous(participants) | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| Mean | 38.5 ± 10.8 | 39.6 ± 10.8 | 44.1 ± 11.1 | 40.0 ± 11.1 |
| Sex: Female, Male(Participants) | Prior Brexpiprazole | Prior Placebo | De Novo | Total |
|---|---|---|---|---|
| Female | 245 | 79 | 85 | 409 |
| Male | 366 | 125 | 172 | 663 |
Showing the first 100 of 148 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2011, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →